<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2020-3-111-116</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1374</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Cognitive impairment and distal polyneuropathy in a patient with diabetes mellitus in neurological outpatient practice</article-title><trans-title-group xml:lang="ru"><trans-title>Когнитивные нарушения и дистальная полиневропатия у пациента с сахарным диабетом в амбулаторной практике невролога</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Косивцова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosivtsova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Косивцова Ольга Владимировна.</p><p>119021, Москва, ул. Россолимо, 11, стр. 1.</p></bio><bio xml:lang="en"><p>Olga Vladimirovna Kosivtsova.</p><p>11, Rossolimo St., Build. 1, Moscow 119021.</p></bio><email xlink:type="simple">o.kosivtsova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Платов</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Platov</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105064, Москва, ул. Казакова, 17А, стр.1.</p></bio><bio xml:lang="en"><p>17A, Kazakov St., Build. 1, Moscow 105064.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочетов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochetov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105064, Москва, ул. Казакова, 17А, стр.1.</p></bio><bio xml:lang="en"><p>17A, Kazakov St., Build. 1, Moscow 105064.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского, Клиника нервных болезней им. А.Я. Кожевникова ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosofsky Institute of Clinical Medicine, A.Ya. Kozhevnikov Clinic of Nervous System Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская поликлиника №46 Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Polyclinic Forty-Six, Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>25</day><month>06</month><year>2020</year></pub-date><volume>12</volume><issue>3</issue><fpage>111</fpage><lpage>116</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kosivtsova O.V., Platov M.P., Kochetov S.A., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Косивцова О.В., Платов М.П., Кочетов С.А.</copyright-holder><copyright-holder xml:lang="en">Kosivtsova O.V., Platov M.P., Kochetov S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1374">https://nnp.ima-press.net/nnp/article/view/1374</self-uri><abstract><p>Cognitive impairment (CI) and distal polyneuropathy are the most common neurological complications of diabetes mellitus (DM) and depend not only on the severity and duration of hyperglycemia, but also on the presence of concomitant diseases. Patients with DM have one or more concomitant diseases that deteriorate the course of each other, and their joint correction improves the patient's status and quality of life. Management of DM patients requires a multidisciplinary approach at the time of diagnosis in order to prevent and identify major complications, to optimize drug therapy, and to use non-pharmacological treatments.</p></abstract><trans-abstract xml:lang="ru"><p>Когнитивные нарушения (КН) и дистальная полиневропатия представляют собой наиболее частые неврологические осложнения сахарного диабета (СД) и зависят не только от тяжести и длительности гипергликемии, но и от наличия сопутствующих заболеваний. Пациенты с СД имеют одно и более сопутствующих заболеваний, которые отягощают течение друг друга, а их совместная коррекция улучшает состояние и качество жизни пациента. При ведении пациентов с СД необходим мультидисциплинар-ный подход с момента установления диагноза для профилактики и выявления основных осложнений, оптимизации лекарственной терапии, применения нефармакологических методов лечения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>неврологические осложнения</kwd><kwd>диабетическая невропатия</kwd><kwd>умеренные когнитивные расстройства</kwd><kwd>деменция</kwd><kwd>лечение</kwd><kwd>альфа-липоевая (тиоктовая) кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>neurological complications</kwd><kwd>diabetic neuropathy</kwd><kwd>moderate cognitive impairment</kwd><kwd>dementia</kwd><kwd>treatment</kwd><kwd>alpha lipoic (thioctic) acid</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией ЗАО «Канонфарма продакшн». Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также принятии решения о представлении статьи для публикации.</funding-statement><funding-statement xml:lang="en">This article has been supported by Kanonfarma prodakshn. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mercer SW, Smith SM, Wyke S, et al. Multimorbidity in primary care: developing the research agenda. Fam Pract. 2009 Apr;26(2): 79-80. doi: 10.1093/fampra/cmp020.</mixed-citation><mixed-citation xml:lang="en">Mercer SW, Smith SM, Wyke S, et al. Multimorbidity in primary care: developing the research agenda. Fam Pract. 2009 Apr;26(2): 79-80. doi: 10.1093/fampra/cmp020.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2. Epub 2012 May 10.</mixed-citation><mixed-citation xml:lang="en">Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2. Epub 2012 May 10.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012 Oct;60(10):E1-E25. doi: 10.1111/j.1532-5415.2012.04188.x. Epub 2012 Sep 19.</mixed-citation><mixed-citation xml:lang="en">Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012 Oct;60(10):E1-E25. doi: 10.1111/j.1532-5415.2012.04188.x. Epub 2012 Sep 19.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-e324. doi: 10.1161/CIR.0000000000000691. Epub 2019 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-e324. doi: 10.1161/CIR.0000000000000691. Epub 2019 Jun 6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53. doi: 10.2337/diacare.27.5.1047.</mixed-citation><mixed-citation xml:lang="en">Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53. doi: 10.2337/diacare.27.5.1047.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7.</mixed-citation><mixed-citation xml:lang="en">Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-e324. doi: 10.1161/CIR.0000000000000691. Epub 2019 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-e324. doi: 10.1161/CIR.0000000000000691. Epub 2019 Jun 6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Furuta A, Ishii N, Nishihara Y, Horie A. Medullary arteries in aging and dementia. Stroke. 1991 Apr;22(4):442-6. doi: 10.1161/01.str.22.4.442.</mixed-citation><mixed-citation xml:lang="en">Furuta A, Ishii N, Nishihara Y, Horie A. Medullary arteries in aging and dementia. Stroke. 1991 Apr;22(4):442-6. doi: 10.1161/01.str.22.4.442.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1565-72. doi: 10.1001/jama.2009.460.</mixed-citation><mixed-citation xml:lang="en">Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1565-72. doi: 10.1001/jama.2009.460.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-2734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20.</mixed-citation><mixed-citation xml:lang="en">Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-2734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee S, Peters SA, Woodward M, Mejia AS, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016 Feb; 39(2):300-7. doi: 10.2337/dc15-1588. Epub 2015 Dec 17.</mixed-citation><mixed-citation xml:lang="en">Chatterjee S, Peters SA, Woodward M, Mejia AS, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016 Feb; 39(2):300-7. doi: 10.2337/dc15-1588. Epub 2015 Dec 17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018 Oct;14(10):591-604. doi: 10.1038/s41574-018-0048-7.</mixed-citation><mixed-citation xml:lang="en">Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018 Oct;14(10):591-604. doi: 10.1038/s41574-018-0048-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011 Jul;91(3):795-826. doi: 10.1152/phys-rev.00042.2009.</mixed-citation><mixed-citation xml:lang="en">Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011 Jul;91(3):795-826. doi: 10.1152/phys-rev.00042.2009.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lindsay ZA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016 Sep;16(9):87. doi: 10.1007/s11892-016-0775-x.</mixed-citation><mixed-citation xml:lang="en">Lindsay ZA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016 Sep;16(9):87. doi: 10.1007/s11892-016-0775-x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28.</mixed-citation><mixed-citation xml:lang="en">Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Erus G, Battapady H, Zhang T, et al. Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose. Diabetes Care. 2015 Jan;38(1):97-104. doi: 10.2337/dc14-1196. Epub 2014 Oct 21.</mixed-citation><mixed-citation xml:lang="en">Erus G, Battapady H, Zhang T, et al. Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose. Diabetes Care. 2015 Jan;38(1):97-104. doi: 10.2337/dc14-1196. Epub 2014 Oct 21.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Boulton AJM. Diabetic neuropathy and foot complications. Handb Clin Neurol. 2014;126: 97-107. doi: 10.1016/B978-0-444-53480-4.00008-4.</mixed-citation><mixed-citation xml:lang="en">Boulton AJM. Diabetic neuropathy and foot complications. Handb Clin Neurol. 2014;126: 97-107. doi: 10.1016/B978-0-444-53480-4.00008-4.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lobmann R. Diabetic foot syndrome. Internist (Berl). 2011 May;52(5):539-48. doi: 10.1007/s00108-010-2733-z.</mixed-citation><mixed-citation xml:lang="en">Lobmann R. Diabetic foot syndrome. Internist (Berl). 2011 May;52(5):539-48. doi: 10.1007/s00108-010-2733-z.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Volmer-Thole M, Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016 Jun 10;17(6):917. doi: 10.3390/ijms17060917.</mixed-citation><mixed-citation xml:lang="en">Volmer-Thole M, Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016 Jun 10;17(6):917. doi: 10.3390/ijms17060917.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005 Mar;48(3):578-85. doi: 10.1007/s00125-004-1663-5. Epub 2005 Feb 24.</mixed-citation><mixed-citation xml:lang="en">Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005 Mar;48(3):578-85. doi: 10.1007/s00125-004-1663-5. Epub 2005 Feb 24.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pfutzner A, Forst T, Engelbach M, et al. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus. Diabet Med. 2001 Jun; 18(6):489-94. doi: 10.1046/j.1464-5491.2001.00524.x.</mixed-citation><mixed-citation xml:lang="en">Pfutzner A, Forst T, Engelbach M, et al. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus. Diabet Med. 2001 Jun; 18(6):489-94. doi: 10.1046/j.1464-5491.2001.00524.x.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001 Nov;44(11):1973-88. doi: 10.1007/s001250100001.</mixed-citation><mixed-citation xml:lang="en">Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001 Nov;44(11):1973-88. doi: 10.1007/s001250100001.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Brown MR, Dyck PJ, McClearn GE, et al. Central and peripheral nervous system complications. 1982;31(Suppl 1 Pt 2):65-70. doi: 10.2337/diab.31.1.s65.</mixed-citation><mixed-citation xml:lang="en">Brown MR, Dyck PJ, McClearn GE, et al. Central and peripheral nervous system complications. 1982;31(Suppl 1 Pt 2):65-70. doi: 10.2337/diab.31.1.s65.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: New insights into pathophysiology and treatment. Muscle Nerve. 2002 Apr;25(4):477-91. doi: 10.1002/mus.10080.</mixed-citation><mixed-citation xml:lang="en">Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: New insights into pathophysiology and treatment. Muscle Nerve. 2002 Apr;25(4):477-91. doi: 10.1002/mus.10080.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042.</mixed-citation><mixed-citation xml:lang="en">Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care.2014;37(1):31-8. doi: 10.2337/dc13-2114.</mixed-citation><mixed-citation xml:lang="en">Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care.2014;37(1):31-8. doi: 10.2337/dc13-2114.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation. 2016 Nov 15;134(20):1579-1594. doi: 10.1161/CIRCULATIONAHA.116.023164. Epub 2016 Oct 11.</mixed-citation><mixed-citation xml:lang="en">Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation. 2016 Nov 15;134(20):1579-1594. doi: 10.1161/CIRCULATIONAHA.116.023164. Epub 2016 Oct 11.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 3;319(13): 1319-1320. doi: 10.1001/jama.2018.0642.</mixed-citation><mixed-citation xml:lang="en">Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 3;319(13): 1319-1320. doi: 10.1001/jama.2018.0642.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Громова ОА, Торшин ИЮ, Калачева АГ и др. Тройственный синергизм этилметил-гидроксипиридина сукцината, магния и витамина В6: молекулярные механизмы. Неврология, нейропсихиатрия, психосоматика. 2017;9(1):42-9. doi: 10.14412/2074-27112017-1-42-49</mixed-citation><mixed-citation xml:lang="en">Gromova OA, Torshin IYu, Kalacheva AG, et al. The triple synergy of ethylmethylhydroxypyridine succinate, magnesium, and vitamin B6: Molecular mechanisms. Nevrologiya, neirop-sikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1): 42-9. (In Russ.). doi: 10.14412/2074-27112017-1-42-49</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11): 2365-70. doi: 10.2337/dc06-1216.</mixed-citation><mixed-citation xml:lang="en">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11): 2365-70. doi: 10.2337/dc06-1216.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Строков ИА, Ахметжанова ЛТ, Солоха ОА. Эффективность лечения диабетической полиневропатии таблетированной формой альфа-липоевой кислоты. Трудный пациент. 2010;8(3):13-8.</mixed-citation><mixed-citation xml:lang="en">Strokov IA, Akhmetzhanova LT, Solokha OA. Effectiveness of treatment of diabetic polyneu ropathy with alpha-lipoic acid tablets. Trudnyi patsient. 2010;8(3):13-8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3. doi: 10.1046/j.1464-5491.1999.00190.x..</mixed-citation><mixed-citation xml:lang="en">Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3. doi: 10.1046/j.1464-5491.1999.00190.x..</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3): 770-6. doi: 10.2337/diacare.26.3.770.</mixed-citation><mixed-citation xml:lang="en">Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3): 770-6. doi: 10.2337/diacare.26.3.770.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2): 114-21. doi: 10.1111/j.1464-5491.2004.01109.x.</mixed-citation><mixed-citation xml:lang="en">Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2): 114-21. doi: 10.1111/j.1464-5491.2004.01109.x.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11): 2365-70. doi: 10.2337/dc06-1216.</mixed-citation><mixed-citation xml:lang="en">Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11): 2365-70. doi: 10.2337/dc06-1216.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Строков ИА, Захаров ВВ, Строков КИ. Диабетическая энцефалопатия. Неврология, нейропсихиатрия, психосоматика. 2012;4(2S):30-40. doi: 10.14412/2074-27112012-2506</mixed-citation><mixed-citation xml:lang="en">Strokov IA, Zakharov VV, Strokov KI. Diabetic encephalopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2S): 30-40. (In Russ.). doi: 10.14412/2074-27112012-2506</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Старчина ЮА, Захаров ВВ. Неврологические осложнения сахарного диабета. Эффективная фармакотерапия. 2019;15(19):30-7.</mixed-citation><mixed-citation xml:lang="en">Starchina YuA, Zakharov VV. Neurological complications of diabetes mellitus. Effektivnaya farmakoterapiya. 2019;15(19):30-7. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
